Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, not recruiting · Phase 3 · NCT04666038
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $487,681
- U.S. investigators named
- 21
- Sites paid
- 14
- Planned or actual enrollment
- 238
About the trial
- Sponsor
- Loxo Oncology, Inc. (with Eli Lilly and Company)
- Tested
- Pirtobrutinib (drug), Idelalisib (drug), Bendamustine (drug), Rituximab (drug)
- Dates
- Started 2021-03-09; completion 2027-05
- Results posted
- Yes
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
From ClinicalTrials.gov, last updated 2026-04-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $487,681 in research payments for this study in 2025 (28 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anita Mazloom, MD Hematology & Oncology · Mobile, AL
- Amol N. Rakkar, M.D. Specialist · Glendale, AZ
- Amol R. Rao, M.D. Hematology & Oncology · Fountain Valley, CA
- Omar Alkharabsheh, MD Hematology & Oncology · Orlando, FL
- Seung Lee, M.D. ENT (Otolaryngology) · Honolulu, HI
- Pablo M. Bedano, MD Medical Oncology · Indianapolis, IN
- Joseph J. Maly, M.D. Hematology & Oncology · Louisville, KY
- Nakhle S. Saba, MD Hematology & Oncology · Baton Rouge, LA
- Zachary A. Sporn, MD Student in an Organized Health Care Education/Training Program · Boston, MA
- Alexandra Hall, MD Internal Medicine · Minneapolis, MN
- Lindsey E. Roeker, M.D. Hematology · Rochester, MN
- Patrick W. Cobb, M.D. Hematology & Oncology · Billings, MT
- Forrest N. Gamble, MD Student in an Organized Health Care Education/Training Program · Durham, NC
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Paul M. Barr, MD Hematology · Rochester, NY
- Bliss J. Chang, MD Cardiology · Albany, NY
- James D'olimpio Hematology & Oncology · Lake Success, NY
- Alejandro Duran Crane, MD Internal Medicine · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
- Julie E. Chang, M.D. Hematology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Strong Memorial Hospital, NY $222,451
- Memorial Sloan-Kettering $93,966
- USA Health University Hospital, AL $68,031
- University of Maryland Baltimore $26,589
- Palo Verde Hematology Oncology LTD $15,170
- Norton Hospitals, Inc, KY $12,433
- Intermountain Health St Vincent Regional Hospital, MT $12,368
- Norton Healthcare Inc $12,341
- Board of Regents of the Univ of Wisconsin Systm $11,023
- Memorial Health Services $3,765
- The Administrators of the Tulane Educational Fund $3,520
- Community Hospital East, IN $3,426
- Clinical Research Alliance Inc $1,606
- Cleveland Clinic, OH $990
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.